Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesSunshine Biopharma Inc

Sunshine Biopharma Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
2.69 USD -0.06 ( 2.18%)
Last update at 2026-11-12T15:03:00Z
VOLUME
14508
Market Cap
3.99M

Momentum Score

…

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.69
Low
2.75
High
52 Week Price Range
1.01
Low
24.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sunshine Biopharma Inc is a small-cap pharmaceutical company listed on NASDAQ; public disclosures indicate engagement in drug development and licensing with limited commercial operations. Long-term growth may be driven by clinical progress, regulatory approvals, strategic partnerships or licensing and eventual commercialization of approved assets. The company may appeal to investors seeking pipeline-driven upside tied to milestones while acknowledging execution and timing uncertainties.

Key risks include clinical and regulatory failure, limited revenues, ongoing financing needs and potential dilution, and low stock liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.75
Dividend Yield
-
Revenue TTM
35.35M
Revenue Per Share
49.67
Gross Profit TTM
10.71M
Debt / Equity
0.04
ROE
-21.92%
Net Debt
-8.31M
ROCE
-25.19%
Diluted EPS TTM
-9.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -5.95M -5.37M -4.11M -26.51M -12.44M
Net income -5.98M -5.13M -4.51M -26.74M -12.77M
Selling general administrative 18.48M 14.00M 10.10M 8.90M 1.87M
Selling and marketing expenses 1.14M 0.94M 0.73M 0.58M -
Gross profit 11.92M 10.67M 8.34M 1.70M 0.11M
Reconciled depreciation 0.33M 0.22M 0.13M 0.03M 0.01M
Ebit -5.95M -5.36M -3.97M -8.67M -2.44M
Ebitda -5.62M -5.14M -3.82M -8.13M -2.43M
Depreciation and amortization 0.33M 0.22M 0.15M 0.54M 0.01M
Operating income -4.48M -5.81M -4.79M -8.67M -2.44M
Other operating expenses 40.78M 40.69M 28.88M 13.02M 2.67M
Interest expense 0.00M 0.01M 0.14M 0.04M 0.33M
Tax provision 0.02M -0.23M 0.41M 0.23M 0.00M
Interest income 0.28M 0.50M 0.74M 0.52M -
Net interest income 0.28M 0.49M 0.60M 0.48M -0.33M
Income tax expense 0.02M -0.23M 0.40M 0.23M 0.33M
Total revenue 36.31M 34.87M 24.09M 4.35M 0.23M
Total operating expenses 16.40M 16.48M 13.12M 10.37M 2.55M
Cost of revenue 24.38M 24.20M 15.75M 2.65M 0.12M
Total other income expense net -1.47M 0.44M 0.67M -17.84M -10.00M
Net income from continuing ops -5.98M -5.13M -26.77M -26.74M -12.44M
Net income applicable to common shares - - - -26.74M -12.44M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 30.08M 30.56M 27.35M 29.24M 2.20M
Intangible assets 1.89M 3.02M 1.44M - -
Other current assets 0.80M 1.13M 0.31M 0.28M 0.04M
Total liab 7.04M 7.06M 6.14M 7.62M 1.99M
Total stockholder equity 23.04M 23.50M 21.21M 21.63M 0.21M
Other current liab 0.30M 0.30M 2.55M 0.50M 0.05M
Common stock 0.00M 0.00M 0.03M 0.02M 0.00M
Capital stock 0.02M 0.02M 0.03M 0.02M 0.10M
Retained earnings -75.02M -69.04M -63.91M -59.40M -32.66M
Other liab - - - 0.04M -
Cash 9.12M 9.69M 16.29M 21.83M 2.05M
Total current liabilities 6.44M 6.31M 5.55M 6.93M 0.09M
Current deferred revenue - - 0.30M - -
Net debt -8.31M -8.73M -15.63M -17.55M -0.15M
Short term debt 0.22M 0.21M 0.12M 3.63M 1.90M
Short long term debt - - - 3.63M -
Short long term debt total 0.81M 0.95M 0.66M 4.27M 1.90M
Other stockholder equity 98.10M 93.35M 84.39M 80.84M 32.79M
Property plant equipment - - - - 0.01M
Total current assets 26.85M 25.97M 24.89M 27.31M 2.20M
Net tangible assets - - - - 0.11M
Net receivables 3.46M 3.87M 2.55M 1.91M 0.01M
Long term debt - - - - 1.90M
Inventory 13.47M 11.28M 5.73M 3.29M 0.11M
Accounts payable 5.66M 5.54M 2.59M 2.80M 0.04M
Accumulated other comprehensive income -0.07M -0.83M 0.70M 0.16M -0.02M
Non currrent assets other -26.85M -25.97M - - 0.01M
Non current assets total 3.23M 4.59M 2.46M 1.93M 0.01M
Capital lease obligations 0.81M 0.95M 0.66M 0.64M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -2.32M -15.01M -14.62M 0.00M
Change to liabilities - - - 0.00M -0.02M
Total cashflows from investing activities -0.84M -2.32M -0.66M -14.62M -14.62M
Net borrowings - 0.35M -0.13M - 2.90M
Total cash from financing activities 4.75M 9.29M 3.43M 39.47M 2.90M
Change to operating activities - - - - -0.00M
Net income -5.98M -5.13M -4.51M -26.74M -12.44M
Change in cash -0.56M -6.61M -5.53M 19.78M 1.06M
Begin period cash flow 9.69M 16.29M 21.83M 2.05M 0.99M
End period cash flow 9.12M 9.69M 16.29M 21.83M 2.05M
Total cash from operating activities -5.33M -12.53M -8.78M -5.25M -1.83M
Issuance of capital stock 1.83M 8.52M -9.10M 30.37M -
Depreciation 0.33M 0.22M 0.15M 0.03M 0.01M
Other cashflows from investing activities -0.84M -0.32M -0.57M - -
Change to inventory -1.64M -6.01M -2.37M 0.04M -0.08M
Change to account receivables -0.12M -2.34M -0.59M -0.52M -0.01M
Sale purchase of stock 0.00M -3.14M -0.54M -0.10M -
Other cashflows from financing activities 4.75M 3.56M 0.01M 13.19M 3.38M
Change to netincome - - - 18.32M 10.70M
Capital expenditures 0.17M 2.32M 0.79M 0.30M 0.00M
Change in working capital -1.45M -5.38M -4.42M 3.15M -0.11M
Other non cash items 1.76M -2.24M -1.44M 18.32M 10.70M
Free cash flow -5.51M -14.85M -9.56M -5.55M -1.83M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SBFM
Sunshine Biopharma Inc		 -0.06
2.18%		 2.69 - - 0.11 0.14 0.02 -7.73
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Sunshine Biopharma Inc

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

333 Las Olas Way, Fort Lauderdale, FL, United States, 33301

954 330 0684

https://sunshinebiopharma.com

50

Name Title Year Born
Dr. Steve N. Slilaty Ph.D. Chairman, CEO & Pres 1952
Mr. Camille Sebaaly CFO & Sec. 1959
Dr. Abderrazzak Merzouki COO & Director 1964
Mr. Robert G. Ferreira Pres of Sunshine Bio Investments Inc 1962
Mr. Camille Sebaaly CFO & Secretary 1959
Dr. Abderrazzak Merzouki Chief Science Officer & Director 1964
Dr. Steve N. Slilaty Ph.D. CEO, President & Chairman 1952
Mr. Marc Beaudoin Chief Operating Officer 1967
Mr. Malek Chamoun Chief Development Officer 1985
Mr. Robert G. Ferreira President of Sunshine Bio Investments Inc 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…